Aldeyra Therapeutics (NASDAQ:ALDX – Get Free Report) and Jaguar Animal Health (NASDAQ:JAGX – Get Free Report) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, dividends, risk, institutional ownership, earnings and analyst recommendations.
Earnings and Valuation
This table compares Aldeyra Therapeutics and Jaguar Animal Health”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Aldeyra Therapeutics | N/A | N/A | -$33.85 million | ($0.46) | -3.61 |
| Jaguar Animal Health | $11.51 million | 0.13 | -$53.43 million | ($1,162.24) | 0.00 |
Institutional & Insider Ownership
59.7% of Aldeyra Therapeutics shares are held by institutional investors. Comparatively, 12.0% of Jaguar Animal Health shares are held by institutional investors. 9.6% of Aldeyra Therapeutics shares are held by company insiders. Comparatively, 2.1% of Jaguar Animal Health shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Analyst Ratings
This is a breakdown of current ratings and target prices for Aldeyra Therapeutics and Jaguar Animal Health, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Aldeyra Therapeutics | 1 | 2 | 1 | 0 | 2.00 |
| Jaguar Animal Health | 1 | 0 | 1 | 0 | 2.00 |
Aldeyra Therapeutics currently has a consensus price target of $5.50, suggesting a potential upside of 231.33%. Jaguar Animal Health has a consensus price target of $2,100.00, suggesting a potential upside of 53,199.49%. Given Jaguar Animal Health’s higher probable upside, analysts clearly believe Jaguar Animal Health is more favorable than Aldeyra Therapeutics.
Profitability
This table compares Aldeyra Therapeutics and Jaguar Animal Health’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Aldeyra Therapeutics | N/A | -57.34% | -36.33% |
| Jaguar Animal Health | -464.20% | -1,194.94% | -114.26% |
Risk & Volatility
Aldeyra Therapeutics has a beta of 1.16, indicating that its stock price is 16% more volatile than the S&P 500. Comparatively, Jaguar Animal Health has a beta of 0.01, indicating that its stock price is 99% less volatile than the S&P 500.
Summary
Aldeyra Therapeutics beats Jaguar Animal Health on 8 of the 11 factors compared between the two stocks.
About Aldeyra Therapeutics
Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-?B, inflammasomes, and Scavenger Receptor A. Reproxalap is being evaluated in Phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis. The company’s clinical pipeline also includes ADX-2191, a dihydrofolate reductase inhibitor in Phase 3 testing for proliferative vitreoretinopathy, and ADX-1612, a chaperome inhibitor in Phase 2 testing for COVID-19 and ovarian cancer.
About Jaguar Animal Health
Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products. The company's products include Mytesi, an anti-secretory antidiarrheal drug for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy; and Canalevia-CA1, a prescription drug product for chemotherapy-induced diarrhea in dogs. It is also developing Crofelemer, an anti-secretory antidiarrheal drug, which is in Phase 3 clinical trial for or prophylaxis of diarrhea in adult cancer patients, and to address rare/orphan disease indications, including short bowel syndrome with intestinal failure and/or congenital diarrheal disorders; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, the company is developing NP-300, a second-generation antidiarrheal drug for symptomatic relief and treatment of moderate-to-severe diarrhea. The company is headquartered in San Francisco, California.
Receive News & Ratings for Aldeyra Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aldeyra Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
